A mouse model of BRCA1-associated breast cancer demonstrated that, in the group of genetically modified animals (Brca1−/−p53−/− mice), BCRP overexpression resulted in acquired resistance to topotecan treatment, whereas its knockdown improved the survival rate of these animals [137]. The gene discussed is ABCG2; the disease is breast carcinoma.